CHRNA3 rs1051730 genotype and short-term smoking cessation.
paper
Cited
Public
Unavailable
- Authors
- Munafò, Marcus R; Johnstone, Elaine C; Walther, Donna; Uhl, George R; Murphy, Michael F G; Aveyard, Paul
- Year
- 2011
- Journal
- Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
- PMID
- 21690317
- DOI
- 10.1093/ntr/ntr106
- PMCID
- PMC3179672
INTRODUCTION: The rs1051730 genetic variant within the CHRNA5-A3-B4 gene cluster is associated with heaviness of smoking and has recently been reported to be associated with likelihood of stopping smoking. We investigated the potential association of rs1051730 genotype with reduced likelihood of smoking cessation in 2 cohorts of treatment-seeking smokers in primary care in the United Kingdom. METHODS: Data were drawn from 2 clinical trials on which DNA was available. One sample was a randomized placebo-controlled trial of nicotine transdermal patch and the other sample an open-label trial where all participants received nicotine transdermal patch. Smoking status was biochemically verified. Logistic regression was used to assess evidence for association in each sample, and data were combined within a meta-analysis. RESULTS: There was evidence of association of rs1051730 genotype with short-term (4-week) cessation in our open-label trial sample but not our placebo-controlled trial sample. When combined in a meta-analysis, this effect remained. There was no evidence of association at later follow-up intervals. Adjustment for cigarette consumption and tobacco dependence did not alter these results substantially. CONCLUSIONS: Our data, taken together with previous recent studies, provide some support for a weak association between this variant and short-term smoking cessation in treatment-seeking smokers, which does not seem to operate only among those receiving nicotine replacement therapy. Moreover, the rs1051730 variant may not merely operate as a marker for dependence or heaviness of smoking.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| CHRNA5-A3-B4 and DRD2 Genes and Smoking Cessation Throughout Adulthood: A Longitudinal Study of Women. | Jones SK et al. | — | 2023 | → |
| Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment. | Chen LS et al. | — | 2023 | → |
| A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation. | Jones SK et al. | — | 2022 | → |
| Efficient estimation of indirect effects in case-control studies using a unified likelihood framework. | Satten GA et al. | — | 2022 | → |
| Efficient Estimation of Indirect Effects in Case-Control Studies Using a Unified Likelihood Framework | Satten GA et al. | — | 2021 | — |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | — | 2021 | → |
| Genes and Eating Preferences, Their Roles in Personalized Nutrition. | Vesnina A et al. | — | 2020 | → |
| Smoking Reduces Plasma Bilirubin: Observational and Genetic Analyses in the Copenhagen General Population Study. | Kodal JB et al. | — | 2020 | → |
| Association Between rs1051730 and Smoking During Pregnancy in Dutch Women. | Mbarek H et al. | — | 2019 | → |
| Determining population stratification and subgroup effects in association studies of rare genetic variants for nicotine dependence. | Hsieh AR et al. | — | 2019 | → |
| Low Smoking Exposure, the Adolescent Brain, and the Modulating Role of CHRNA5 Polymorphisms. | Chaarani B et al. | — | 2019 | → |
| Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women. | Tomaz PRX et al. | — | 2018 | → |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | — | 2018 | → |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | — | 2018 | → |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | — | 2018 | → |
| Toward the implementation of genomic applications for smoking cessation and smoking-related diseases. | Ramsey AT et al. | — | 2018 | → |
| Does High Tobacco Consumption Cause Psychological Distress? A Mendelian Randomization Study. | Skov-Ettrup LS et al. | — | 2017 | → |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | — | 2017 | → |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | — | 2017 | → |
| Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not? | Kranzler HR et al. | — | 2017 | → |
| Contribution of Variants in CHRNA5/A3/B4 Gene Cluster on Chromosome 15 to Tobacco Smoking: From Genetic Association to Mechanism. | Wen L et al. | — | 2016 | → |
| Converging findings from linkage and association analyses on susceptibility genes for smoking and other addictions. | Yang J et al. | — | 2016 | → |
| Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis. | Chen LS et al. | — | 2016 | → |
| Smokescreen: a targeted genotyping array for addiction research. | Baurley JW et al. | — | 2016 | → |
| A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. | Jensen KP et al. | — | 2015 | → |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | — | 2015 | → |
| CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. | Chen LS et al. | — | 2015 | → |
| Effect of smoking on physical and cognitive capability in later life: a multicohort study using observational and genetic approaches. | North TL et al. | — | 2015 | → |
| Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis. | Leung T et al. | — | 2015 | → |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | — | 2015 | → |
| Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. | Tyndale RF et al. | — | 2015 | → |
| New mechanisms and perspectives in nicotine withdrawal. | Jackson KJ et al. | — | 2015 | → |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | — | 2015 | → |
| The association of rs1051730 genotype on adherence to and consumption of prescribed nicotine replacement therapy dose during a smoking cessation attempt. | Ware JJ et al. | — | 2015 | → |
| The value of control conditions for evaluating pharmacogenetic effects. | Chen LS et al. | — | 2015 | → |
| A glimpse into the future - Personalized medicine for smoking cessation. | Bierut LJ et al. | — | 2014 | → |
| Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. | Zhu AZ et al. | — | 2014 | → |
| CHRNA5 variant predicts smoking cessation in patients with acute myocardial infarction. | Chen LS et al. | — | 2014 | → |
| Commentary on Chen et al. (2014): another step on the road to clinical utility of pharmacogenetics for smoking cessation? | David SP | — | 2014 | → |
| Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction. | Chen LS et al. | — | 2014 | → |
| Investigating the possible causal association of smoking with depression and anxiety using Mendelian randomisation meta-analysis: the CARTA consortium. | Taylor AE et al. | — | 2014 | → |
| Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. | Leventhal AM et al. | — | 2014 | → |
| Nicotinic receptor modulation to treat alcohol and drug dependence. | Rahman S et al. | — | 2014 | → |
| Partner smoking and maternal cotinine during pregnancy: implications for negative control methods. | Taylor AE et al. | — | 2014 | → |
| Stratification by smoking status reveals an association of CHRNA5-A3-B4 genotype with body mass index in never smokers. | Taylor AE et al. | — | 2014 | → |
| Biomarkers for smoking cessation. | Bough KJ et al. | — | 2013 | → |
| Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. | Carpenter MJ et al. | — | 2013 | → |
| Environmental and genomic factors as well as interventions influencing smoking cessation: a systematic review of reviews and a proposed working model. | de Viron S et al. | — | 2013 | → |
| Genomics and personalized medicine: <i>CHRNA5-CHRNA3-CHRNB4</i> and smoking cessation treatment. | Chen LS et al. | — | 2013 | → |
| Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. | Bergen AW et al. | — | 2013 | → |
| Polygenic risk and the developmental progression to heavy, persistent smoking and nicotine dependence: evidence from a 4-decade longitudinal study. | Belsky DW et al. | — | 2013 | → |
| The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism. | Petrovsky N et al. | — | 2013 | → |
| Translational research in nicotine dependence. | Turner JR et al. | — | 2013 | → |
| Using Mendelian randomisation to infer causality in depression and anxiety research. | Gage SH et al. | — | 2013 | → |
| Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. | Munafò MR et al. | — | 2012 | → |
| Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation. | Spruell T et al. | — | 2012 | → |
| From men to mice: CHRNA5/CHRNA3, smoking behavior and disease. | Ware JJ et al. | — | 2012 | → |
| Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. | Chen LS et al. | — | 2012 | → |
| Mouse models for studying genetic influences on factors determining smoking cessation success in humans. | Hall FS et al. | — | 2012 | → |
| Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. | Gold AB et al. | — | 2012 | → |
| The genetic basis of addictive disorders. | Ducci F et al. | — | 2012 | → |